Key facts
- This page summarizes Daniel Lynch's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Feb 2025, 19:59.
Daniel Lynch - 10 Feb 2025 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- Director
- Issuer ticker
- SWTX
- Reported as of
- 10 Feb 2025
- Net transaction value
- -$9,530,351
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2025, 19:59:41 UTC
- Prior SEC filing
- 17 May 2024
- Next SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis I. Perier, Jr. as Attorney-in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Lynch filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 12 Feb 2025.
Change
- Previous filing in this sequence was filed on 17 May 2024.
- Current net transaction value: -$9,530,351.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Sale
- Transaction value
- $3,713,553
- Shares
- -69,766
- Change %
- -23%
- Price
- $53.23
- Shares after
- 236,178
- Date
- 10 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
SWTX
transaction
Common Stock
Sale
- Transaction value
- $2,175,047
- Shares
- -39,634
- Change %
- -17%
- Price
- $54.88
- Shares after
- 196,544
- Date
- 10 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F3
SWTX
transaction
Common Stock
Sale
- Transaction value
- $3,641,751
- Shares
- -65,600
- Change %
- -33%
- Price
- $55.51
- Shares after
- 130,944
- Date
- 10 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 3, 2024.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.28 to $55.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F4
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.40 to $55.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.